MEDIPOST announced on 15 May that they have obtained US patent for cartilage differentiation capability selection technology of cord blood originated stem cell which is raw material for arthritis treatment drug ‘CARTISTEM^®’

This patent is regarding ‘Method of selecting stem cells having high chondrogenic differentiation capability’ an is utilized in the manufacturing process of ‘CARTISTEM^®’. MEDIPOST disclosed that this technology will be helpful not only for quality maintenance of the stem cell treatment but also with product upgrade such as improvement of efficacy.

This patented technology has meaning in the fact that it has discovered and systemized the fact that the stem cell extracted from cord blood and cultivated maintains the cartilage differentiation capability by adjusting the differentiation to cartilage cell by excreting particular proteins.

In relation to such, MEDIPOST personnel stated that “we are applying this technology in clinical trial of ‘CARTISTEM^®’ being carrie out in US under approval of FDA” and “we anticipate that it will become a chance to have recognition in US for stem cell treatment drug production technology such as ‘CARTISTEM^®’